intro image

Cystic Fibrosis & Antimicrobial Susceptibility Testing  (AST) Resources

Webinar: Trends in Bacterial Resistance and New Antibiotic Treatments for Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis

This webinar, originally presented on May 29, 2019, aims to list problem bacterial pathogens in CF patients and other current resistance trends in this population, describe challenges with microbiological identification and susceptibility testing of CF pathogens, and identify new antibiotics that may play a role in the treatment of acute pulmonary exacerbations in patients with CF. Access the webinar on demand here.


AST Price List Antimicrobial Prescribing Booklet Enhanced Targeted Therapy for CF Patients Flyer Antimicrobial Stewardship Booklet

About Cystic Fibrosis 

Cystic Fibrosis (CF) affects approximately 70,000 children and adults worldwide and is the most frequently- occurring genetic life-shortening disease in Caucasians. While CF is a multi-organ disease, it is the decline in pulmonary function as a result of chronic infection that results in significant morbidity and mortality.

Non-fermenting Gram-negative pathogens such as Pseudomonas aeruginosa are responsible for chronic lung infections in over 80% of CF patients. Unfortunately, antibiotic resistance among CF pathogens continues to increase. Proper identification of the infecting organism and antimicrobial susceptibility testing are vital in selecting appropriate antibiotic therapy to successfully treat acute pulmonary exacerbations.

To learn more about bioMérieux’s well-established method for antimicrobial susceptibility testing, visit the product page.